Rare Daily Staff
NeuBase Therapeutics, which is developing in vivo gene editing therapies that don’t trigger an immune response, said its board of directors has halted further development of the company’s programs to conduct a comprehensive exploration of strategic alternatives.
The decision comes after a review of the company’s business, including the status of its programs, resources, and capabilities. It also comes just one month after Neubase completed a $5 million private placement through a registered direct offering of stock and warrants for an aggregate of 1.9 million shares.
NeuBase is developing precision genetic medicines targeting rare, monogenic diseases, for which there are no approved therapies, as well as more common genetic disorders, including cancers.
Its pipeline includes therapeutic candidates for in vivo gene editing to correct mutations using its “stealth” gene editing designed to avoid being identified by the immune system while providing pronounced effects that are safe, delivered with non-viral technologies, and broadly applicable across different mutation types and industries.
The company has said that its technology can potentially address up to 90 percent of all known human mutations, including insertions, deletions, transitions, and transversions. NeuBase’s pipeline also includes gene silencing treatments for myotonic dystrophy type 1, Huntington’s disease; and cancer-driving point mutations, such as KRAS G12V and G12D, which are involved in many tumor types. All of its programs are preclinical.
As part of the evaluation process, the board will explore potential strategic alternatives for the company that may include, but are not limited to, an acquisition, merger, business combination, or other transaction.
Photo: Dietrich Stephan, CEO of Neubase
Stay Connected
Sign up for updates straight to your inbox.